Physician profile
Aliya Hot
NPI 1023284833
$1,404.10
in general payments reported to CMS, 2019-2025
12 companies · $74.67 in 2025
The $74.67 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.21 · 2021: $12.81 · 2022: $315 · 2023: $186 · 2024: $800 · 2025: $74.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,060.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $345.48 | 2024-2025 | Tepezza |
| Glaukos Corporation | $274.89 | 2024 | Ce-Marked Kxla System |
| Coopervision INC. | $216.89 | 2022-2024 | Myday Contact Lens |
| Horizon Therapeutics Plc | $152.98 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $136.43 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $79.54 | 2022 | |
| Alcon Vision LLC | $66.22 | 2024-2025 | Simbrinza, Tryptyr |
| Harrow Eye, LLC | $46.30 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $39.89 | 2023-2025 | Vyzulta, Miebo |
| Eyevance Pharmaceuticals LLC | $17.46 | 2022 | |
| Shire North American Group INC | $15.21 | 2019 | |
| Allergan, INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Hot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.